ASX Share rice
Sat 08 Aug 2020 - 04:38:pm (Sydney)

AVH Share Price

AVITA MEDICAL LTDAVHPharmaceuticals, Biotechnology & Life Sciences

AVH Company Information

Name:

AVITA Therapeutics, Inc

Sector:

Healthcare

Industry:

Medical Devices

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

21 North Mole Drive North Fremantle WA Australia 6159

Phone:

61 8 6168 8400

Chief Exec. Officer:

Mr. Jonathan Fievez BEng (Mecht)

Non Exec. Director & Company Sec.:

Mr. Grant Jonathan Mooney C.A., BBus, CA

Interim CFO & Commercial Mang.:

Ms. Rebecca Cutter

Chief Operating Officer:

Mr. David Kessel

Admin. Mang.:

Ms. Tegan Brookman Dip. Bus Mngt, Cert Iv Bus

Company Overview:

Carnegie Clean Energy Limited develops and commercializes the CETO wave energy technology for converting ocean wave energy into zero-emission electricity worldwide. It also produces and sells clean renewable energy using solar-battery systems to the Department of Defense. The company was formerly known as Carnegie Wave Energy Limited and changed its name to Carnegie Clean Energy Limited in December 2016. Carnegie Clean Energy Limited is based in North Fremantle, Australia.

AVH Share Price Information

Shares Issued:

533.36M

Market Capitalisation:

$3.52B

Revenue (TTM):

$15.58M

Revenue Per Share (TTM):

$0.15

Earnings per Share:

$-0.028

Profit Margin:

-2.604

Operating Margin (TTM):

$-2.64

Return On Assets (TTM):

$-0.30

Return On Equity (TTM):

$-0.52

Quarterly Revenue Growth (YOY):

4.341

Gross Profit(TTM):

$6.01M

Diluted Earnings Per Share (TTM):

$-0.002

AVH CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-1,794,610

Change To Liabilities:

$-2,129,676

Total Cashflow From Investing Activities:

$-1,744,153

Net Borrowings:

$850K

Net Income:

$-35,160,227

Total Cash From Operating Activities:

$-4,383,412

Depreciation:

$250.99K

Change To Inventory:

$-464,937

Change To Account Receivables:

$-4,299,157

Capital Expenditures:

$1.79M

AVH Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-35,340,090

Net Income:

$-35,160,227

Gross Profit:

$6.01M

Operating Income:

$-35,759,016

Other Operating Expenses:

$-8,259,152

Interest Expense:

$37.77K

Income Tax Expense:

$-179,863

Total Revenue:

$7.71M

Total Operating Expenses:

$43.46M

Cost Of Revenue:

$1.70M

AVH Balance Sheet

Balance Sheet Date:

2019-06-30

Intangible Assets:

$320.68K

Total Liabilities:

$6.95M

Total Stockholder Equity:

$29.79M

Other Current Liabilities:

$650.36K

Total Assets:

$36.74M

Common Stock:

$194.46M

Other Current Assets:

$200.87K

Retained Earnings:

$-183,753,106

Other Liabilities:

$49.48K

Other Assets:

$1.95M

Cash:

$28.98M

Total Current Liabilities:

$6.28M

Short-Term Debt:

$4.39M

Property - Plant & Equipment:

$2.68M

Net Tangible Assets:

$-5,609,191

Long-Term Investments:

$12.41K

Total Current Assets:

$34.58M

Net Receivables:

$2.12M

Short-Term Investments:

$2.16M

Inventory:

$1.06M

Accounts Payable:

$679.11K

Non Currrent Assets (Other):

$2.16M

Short-Term Investments:

$2.16

Non Current Liabilities Total:

$664.73K

AVH Share Price History

AVH News

29 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL) (ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the Canaccord Genuity 40th Annual Virtual Growth Conference on 12 August 2020 at 8:30 a.m. EDT.
13 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that the Biomedical Advanced Research and Development Authority (BARDA), a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), will procure the RECELL® System as part of the HHS mission to build preparedness for public health emergencies.
09 Jul, 2020
AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today preliminary unaudited results for the fourth quarter and full year ended June 30, 2020, together with a company update.
08 Jul, 2020
A look at the shareholders of AVITA Therapeutics, Inc. (ASX:AVH) can tell us which group is most powerful...
29 Jun, 2020
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the scheme of arrangement to effect the redomiciliation of the Company and its subsidiaries (Avita Group) from Australia to the United States of America (Scheme) has today been implemented. As previously announced, the Scheme was approved by the Company’s shareholders at the Scheme meeting held via live webcast on 15 June 2020 and approved by the Federal Court of Australia on 22 June 2020.
22 Jun, 2020
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to announce that the Federal Court of Australia (Court) has today approved the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries (Avita Group) from Australia to the United States of America (Scheme), under which AVITA Therapeutics, Inc. ARBN 641 288 155 (Avita US), a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.
15 Jun, 2020
AVITA Medical Limited Proposed redomiciliation to the United States of America - Results of Scheme Meeting
10 Jun, 2020
AVITA Medical Limited ACN 058 466 523 (Company) is pleased to confirm that the general meeting to consider a resolution to approve the proposed scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America (Scheme Meeting) is being held by way of live webcast at 9.00am (AEST) on Monday, 15 June 2020 (being 7.00pm (EDT) on Sunday, 14 June 2020).
05 Jun, 2020
AVITA Medical Limited Proposed redomiciliation to the United States of America – Satisfaction of FIRB Condition
02 Jun, 2020
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.
27 May, 2020
In this article you are going to find out whether hedge funds think Avita Medical Limited (NASDAQ:RCEL) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]
21 May, 2020
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
13 May, 2020
AVITA Medical to Participate at Oppenheimer's MedTech Summit
11 May, 2020
AVITA Medical Limited (Company) (ASX:AVH) (NASDAQ:RCEL) is pleased to announce that the Australian Securities and Investments Commission (ASIC) has registered the scheme booklet (Scheme Booklet) in relation to the proposed scheme of arrangement under which AVITA Therapeutics, Inc. (Avita US), a newly-formed company incorporated in Delaware in the United States of America, will become the parent company of the Company and its subsidiaries (Avita Group) for the purposes of effecting a redomiciliation of the Avita Group from Australia to the United States of America (Scheme).
AVITA Medical Limited Proposed redomiciliation to the United States of America – Federal Court of Australia orders convening of Scheme Meeting
10 May, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
02 May, 2020
Identifying tomorrow's stock market winners requires unwavering curiosity. Using its innovations in skin regeneration technology, Australia-based Avita Medical (NASDAQ: RCEL) has created an alternative to skin grafts that involves less time, pain, and risk of infection. Avita's medical device, called the RECELL system, prepares a spray-on suspension using a small amount of a patient's own skin.
29 Apr, 2020
AVITA Medical Reports Third Quarter Fiscal 2020 Financial Results and Company Update
20 Apr, 2020
AVITA Medical Announces Intention to Redomicile to the United States of America
06 Apr, 2020
AVITA Medical Provides Preliminary Top Line Results for the Third Quarter and COVID-19 Update